Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Myriad Genetics, Inc.

Market Cap 429M 374M 346M 324M 608M 40.46B 612M 4.11B 1.59B 19.92B 1.61B 1.58B 69.15B P/E 2026 *
-5.97x
P/E 2027 * -8.57x
Enterprise Value 429M 374M 346M 324M 608M 40.46B 612M 4.11B 1.59B 19.92B 1.61B 1.58B 69.15B EV / Sales 2026 *
0.5x
EV / Sales 2027 * 0.47x
Free-Float
96.22%
Yield 2026 *
-
Yield 2027 * -
1 day+3.65%
1 week+4.85%
Current month+14.36%
1 month+16.11%
3 months-0.87%
6 months-30.69%
Current year-26.18%
1 week 4.21
Extreme 4.21
4.58
1 month 3.72
Extreme 3.72
4.78
Current year 3.53
Extreme 3.53
7.15
1 year 3.53
Extreme 3.53
8.59
3 years 3.53
Extreme 3.53
29.3
5 years 3.53
Extreme 3.53
36.95
10 years 3.53
Extreme 3.53
50.44
Manager TitleAgeSince
Chief Executive Officer 54 2025-04-29
Director of Finance/CFO 43 2025-08-15
Chief Tech/Sci/R&D Officer - 2026-05-31
Director TitleAgeSince
Chairman 67 2020-03-22
Director/Board Member 71 2010-06-09
Director/Board Member 66 2019-09-24
Date Insider Type Main position Quantity % Market Cap.
06-10Free

Executive/Senior Manager

5,000 0.0053%
06-10Free

Chief Executive Officer

3,542 0.0038%
06-07Sell

Director

-15,000 0.0159%
Change 5-day change 1-year change 3-year change Capi.($)
+3.65%+4.85%-7.72%-80.12% 429M
+2.07%+0.12%+168.17%+260.45% 17.47B
+2.15%+1.85%-42.64%-23.44% 9.33B
+0.65%-0.63%+31.15%+12.65% 6.76B
+3.42%+2.78%-32.22% - 5.22B
-1.64%-3.63%-27.65%-32.18% 4.88B
+10.00%+20.71%+105.80%+106.31% 4.54B
+8.17%+20.51%+221.51%-37.63% 4.41B
0.00%-2.17%-31.05%-33.00% 3.95B
-1.74%-2.46%-17.42%-42.80% 2.57B
Average +2.67%+3.48%+36.79%+14.47% 5.96B
Weighted average by Cap. +2.50%+3.14%+62.69%+79.16%

Financials

2026 *2027 *
Net sales 864M 753M 697M 653M 1.22B 81.48B 1.23B 8.27B 3.21B 40.11B 3.24B 3.17B 139B 916M 799M 740M 692M 1.3B 86.42B 1.31B 8.77B 3.4B 42.53B 3.44B 3.36B 148B
Net income -71.48M -62.32M -57.72M -54.04M -101M -6.74B -102M -685M -265M -3.32B -268M -263M -11.53B -50.98M -44.45M -41.17M -38.54M -72.27M -4.81B -72.71M -488M -189M -2.37B -191M -187M -8.22B
Net Debt - -
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
26-06-18 4.540 $ +3.65% 2,436,337
26-06-17 4.380 $ +3.06% 876,791
26-06-16 4.250 $ -1.62% 1,273,711
26-06-15 4.320 $ -0.23% 1,128,294
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
4.540USD
Average target price
6.250USD
Spread / Average Target
+37.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!